| |
Exploratory Development
(Post discovery through Phase II) |
Full Development (Registrational, Filed) |
Marketed Product Development (Approved in at least one major market) |
| Adnectin Bispecific (oncology) |
Ipilimumab (oncology) |
SPRYCEL® (dasatinib)
(oncology) |
| VEGF R-2 Adnectin (oncology) |
Brivanib (oncology) |
ERBITUX® (cetuximab)
(oncology) |
| ErbB/VEGF inhibitor (oncology) |
Necitumumab (oncology) |
IXEMPRA® (ixabepilone) (oncology) |
| JAK2 inhibitor (oncology) |
Dapagliflozin (metabolics) |
ONGLYZA™ (saxagliptin) (metabolics) |
| IGF-1R antagonist (oncology) |
Belatacept (immunoscience) |
ORENCIA® (abatacept) (immunoscience) |
| SMO antagonist (oncology) |
Apixaban (cardiovascular) |
PLAVIX® (clopidogrel bisulfate tablets) (cardiovascular) |
| Cdc7 inhibitor (oncology) |
|
AVAPRO® (irbesartan) AVALIDE® (irbesartan-
hydrochlorothiazide) (cardiovascular) |
|
RAF Kinase inhibitor (oncology)
|
|
BARACLUDE® (entecavir) (virology) |
| Elotuzumab (Anti-CS1) (oncology) |
|
REYATAZ® (atazanavir sulfate) (virology) |
| Anti-CD137 (oncology) |
|
SUSTIVA® (efavirenz) ATRIPLA® (efavirenz / emtricitabine / tenofovir disoproxil fumarate) (virology) |
| Anti-CD19 (oncology) |
|
ABILIFY® (aripiprazole) (neuroscience) |
| Anti-PDL1 (oncology) |
|
|
|
Anti-PD1 (oncology)
|
|
|
| Anti-CD70 ADC (oncology) |
|
|
| Anti-CXCR4 (oncology) |
|
|
| Notch inhibitor (oncology) |
|
|
| MCHR1 antagonist (metabolics) |
|
|
| Glucokinase activator (metabolics) |
|
|
| 11βHSD inhibitors (metabolics) |
|
|
| DGAT inhibitor (metabolics) |
|
|
| CCR2 antagonist (metabolics) |
|
|
| GPR119 agonist (metabolics) |
|
|
| CCR1 antagonists (immunoscience) |
|
|
| p38 Kinase inhibitor (immunoscience) |
|
|
| Anti-CD28 (immunoscience) |
|
|
| Anti-IL6 (immunoscience) |
|
|
| IL-23 Adnectin (immunoscience) |
|
|
| Anti-IFNα (immunoscience) |
|
|
| Anti-IP10 (immunoscience) |
|
|
| LXR modulators (cardiovascular) |
|
|
| PCSK9 inhibitor (cardiovascular) |
|
|
| CCR2 / 5 antagonist(cardiovascular) |
|
|
| IKACh inhibitor (cardiovascular) |
|
|
| Delta PKC inhibitor (cardiovascular) |
|
|
| NS3 inhibitor (virology) |
|
|
| NS5B inhibitor (virology) |
|
|
| NS5A inhibitors (virology) |
|
|
PEG Interferon λ
(virology) |
|
|
| HIV Attachment inhibitor (virology) |
|
|
| Triple Reuptake inhibitors (neuroscience) |
|
|
| Microtubule stabilizer (neuroscience) |
|
|
| Gamma Secretase inhibitor (neuroscience) |
|
|
| AGN-209323 (neuroscience) |
|
|
| CGRP antagonist (neuroscience) |
|
|
| |